米国の急性期用脳室ドレーンの市場規模、シェア、動向分析レポート：用途別、患者タイプ別、セグメント予測、2025～2030年

市場規模と動向：

米国の急性期用脳室ドレーンの市場規模は2024年に8,650万米ドルとなり、2025～2030年にかけてCAGR 7.9％で成長すると予測されています。

この成長は、非外傷性水頭症の有病率の上昇、最小侵襲性または非侵襲性神経外科手術に対する需要の増加、技術的に改良されたデバイスの採用率の上昇によってもたらされると予測されます。事故、スポーツ外傷、脳卒中の発生率の増加に伴い、体外式脳室ドレーン（EVD）処置の需要は着実に増加しています。

高齢化社会の拡大に伴い、脳卒中や動脈瘤などの疾患の有病率が上昇し、EVD処置の必要性がさらに高まっています。例えば、世界銀行グループによると、米国の65歳以上の総人口は2018年に4,998万人で、2023年には5,838万人に増加しました。また、ヘルスケアインフラの進歩や、急性神経症状に対応できる設備を備えた救急・外傷センターの増加も市場成長に寄与しています。

改良されたカテーテル設計、抗菌コーティング、統合モニタリング機能など、EVDシステムの技術革新は患者の転帰を向上させ、感染リスクを低減するため、これらのデバイスはヘルスケアプロバイダーにとってより魅力的なものとなっています。病院や診療所では、治療効率を高め合併症を最小限に抑えるため、こうした先進的なEVDシステムを採用するケースが増えています。さらに、低侵襲脳外科手術が重視されるようになっていることも、EVDの需要を後押ししています。EVDは従来の手術法よりも低侵襲で髄液排出を管理できるためです。

市場拡大を後押しするもう一つの要因は、米国におけるヘルスケア支出の増加と、神経学的処置に対する有利な償還政策です。メディケア・メディケイドサービスセンターによると、米国の医療支出は2023年に7.5％増加し、4兆9,000億米ドルに達し、これは1人当たり1万4,570米ドルに相当します。EVDの装着や関連治療が保険適用されることで、患者へのアクセスが広がり、病院がこれらの機器に投資することが促進されます。さらに、クリティカルケア環境における早期かつ効果的な髄液管理の利点に対する医師の意識が高まることで、採用率が高まっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の急性期用脳室ドレーン市場の変数、動向、および範囲

• 市場系統の展望
  • 親市場の展望
  • 関連/付随市場の展望
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 米国の急性期用脳室ドレーン市場の分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
• 米国の急性期用脳室ドレーン市場：パイプライン分析

第4章 米国の急性期用脳室ドレーン市場：用途別の推定・動向分析

• 用途別のセグメントダッシュボード
• 米国の急性期用脳室ドレーン市場：用途別の変動分析
• 米国の急性期用脳室ドレーン市場規模と動向分析（用途別、2018～2030年）
• 外傷性脳損傷
• くも膜下出血
• 脳内出血
• その他の非外傷性水頭症

第5章 米国の急性期用脳室ドレーン市場：患者タイプ別の推定・動向分析

• 患者タイプ別のセグメントダッシュボード
• 米国の急性期用脳室ドレーン市場：患者タイプ別の変動分析
• 米国の急性期用脳室ドレーン市場規模と動向分析（患者タイプ別、2018～2030年）
• 小児
• 成人

第6章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • Key company heat map analysis, 2024
• 企業プロファイル
  • Medtronic
  • Integra LifeSciences Corporation
  • Anuncia Medical, Inc.
  • Natus
  • Fuji Systems
  • B Braun/Aesculap
  • Boston Scientific
  • Abbott

List of Tables

• Table 1 List of abbreviations
• Table 2 U.S. acute external ventricular drain market, by application, 2018-2030 (USD Million)
• Table 3 U.S. acute external ventricular drain market, by patient type, 2018-2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 U.S. acute external ventricular drain market: market outlook
• Fig. 10 U.S. acute external ventricular drain competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 U.S. acute external ventricular drain market driver impact
• Fig. 16 U.S. acute external ventricular drain market restraint impact
• Fig. 17 U.S. acute external ventricular drain market strategic initiatives analysis
• Fig. 18 U.S. acute external ventricular drain market: Application movement analysis
• Fig. 19 U.S. acute external ventricular drain market: Application outlook and key takeaways
• Fig. 20 Traumatic brain injury market estimates and forecasts, 2018 - 2030
• Fig. 21 Subarachnoid hemorrhage market estimates and forecasts, 2018 - 2030
• Fig. 22 Intracerebral hemorrhage market estimates and forecasts, 2018 - 2030
• Fig. 23 Other non-traumatic hydrocephalus conditions market estimates and forecasts, 2018 - 2030
• Fig. 24 U.S. acute external ventricular drain market: Patient Type movement analysis
• Fig. 25 U.S. acute external ventricular drain market: Patient Type outlook and key takeaways
• Fig. 26 Pediatric market estimates and forecasts, 2018 - 2030
• Fig. 27 Adult market estimates and forecasts, 2018 - 2030

Market Size & Trends:

The U.S. acute external ventricular drain market size was valued at USD 86.5 million in 2024 and is projected to grow at a CAGR of 7.9% from 2025 to 2030. The growth is expected to be driven by the rising prevalence of non-traumatic hydrocephalus, increased demand for minimal or noninvasive neurosurgeries, and the rising adoption of technologically improved devices. With the growing incidence of accidents, sports injuries, and strokes, the demand for external ventricular drain (EVD) procedures is rising steadily.

As the aging population expands, the prevalence of conditions like strokes and aneurysms rises, further boosting the need for EVD procedures. For instance, according to the World Bank Group, the total population aged 65 and above in the U.S. was 49.98 million in 2018, increasing to 58.38 million in 2023. In addition, advancements in healthcare infrastructure and the rising number of emergency and trauma centers equipped to handle acute neurological cases contribute to market growth.

Technological innovations in EVD systems, such as improved catheter designs, antimicrobial coatings, and integrated monitoring capabilities, enhance patient outcomes and reduce infection risks, making these devices more appealing to healthcare providers. Hospitals and clinics increasingly adopt these advanced EVD systems to improve treatment efficiency and minimize complications. Moreover, the growing emphasis on minimally invasive neurosurgical techniques supports the demand for EVDs, as they offer a less invasive solution for managing CSF drainage than traditional surgical methods.

Another factor fueling market expansion is the rising healthcare expenditure in the U.S., coupled with favorable reimbursement policies for neurological procedures. According to the Centers for Medicare & Medicaid Services, U.S. healthcare spending increased by 7.5% in 2023, reaching USD 4.9 trillion, which amounts to USD 14,570 per person. Insurance coverage for EVD placements and related treatments ensures broader patient access, encouraging hospitals to invest in these devices. Furthermore, increased physician awareness about the benefits of early and effective CSF management in critical care settings drives higher adoption rates.

U.S. Acute External Ventricular Drain Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. acute external ventricular drain market report based on application, and patient type.

• Application Outlook (Revenue, USD Million, 2018 - 2030)
• Traumatic Brain Injury
• Subarachnoid hemorrhage
• Intracerebral hemorrhage
• Other Non-Traumatic Hydrocephalus conditions
• Patient Type Outlook (Revenue, USD Million, 2018 - 2030)
• Pediatric
• Adult

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Patient Type
  • 1.2.3. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Application outlook
  • 2.2.2. Patient type outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Acute External Ventricular Drain Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. U.S. Acute External Ventricular Drain Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
• 3.4. U.S. Acute External Ventricular Drain Market: Pipeline Analysis

Chapter 4. U.S. Acute External Ventricular Drain Market: Application Estimates & Trend Analysis

• 4.1. Application Segment Dashboard
• 4.2. U.S. Acute External Ventricular Drain Market: Application Movement Analysis
• 4.3. U.S. Acute External Ventricular Drain Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
• 4.4. Traumatic Brain Injury
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
• 4.5. Subarachnoid Hemorrhage
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Intracerebral Hemorrhage
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Other Non-Traumatic Hydrocephalus Conditions
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Acute External Ventricular Drain Market: Patient Type Estimates & Trend Analysis

• 5.1. Patient Type Segment Dashboard
• 5.2. U.S. Acute External Ventricular Drain Market: Patient Type Movement Analysis
• 5.3. U.S. Acute External Ventricular Drain Market Size & Trend Analysis, by Patient Type, 2018 to 2030 (USD Million)
• 5.4. Pediatric
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Adult
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. Key company heat map analysis, 2024
• 6.4. Company Profiles
  • 6.4.1. Medtronic
    • 6.4.1.1. Company overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Product benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. Integra LifeSciences Corporation
    • 6.4.2.1. Company overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Product benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Anuncia Medical, Inc.
    • 6.4.3.1. Company overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Product benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. Natus
    • 6.4.4.1. Company overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Product benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Fuji Systems
    • 6.4.5.1. Company overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Product benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. B Braun/Aesculap
    • 6.4.6.1. Company overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Product benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Boston Scientific
    • 6.4.7.1. Company overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Product benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. Abbott
    • 6.4.8.1. Company overview
    • 6.4.8.2. Financial performance
    • 6.4.8.3. Product benchmarking
    • 6.4.8.4. Strategic initiatives